• Explore /
  • Poster
  • / Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study.

Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study.

Abstract Poster

Authors

null

Jeff P. Sharman

Willamette Valley Cancer Institute and US Oncology Research Center, Eugene, OR

Jeff P. Sharman , Danielle M. Brander , Anthony R. Mato , Nilanjan Ghosh , Stephen J. Schuster , Suman Kambhampati , John M. Burke , Frederick Lansigan , Marshall T. Schreeder , Scott D Lunin , Alexander Zweibach , Mikhail Shtivelband , Patrick M. Travis , Jason Claud Chandler , Kathryn S. Kolibaba , Peter Sportelli , Hari P. Miskin , Michael S. Weiss , Ian Flinn

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Chronic Lymphocytic Leukemia (CLL) and Hairy Cell

Clinical Trial Registration Number

NCT02301156

Citation

J Clin Oncol 38: 2020 (suppl; abstr 8022)

DOI

10.1200/JCO.2020.38.15_suppl.8022

Abstract #

8022

Poster Bd #

355

Abstract Disclosures

Similar Posters

First Author: Jeffrey Alan Jones

First Author: Meletios A. Dimopoulos

First Author: Michael Wang

First Author: Ömür Gökmen Sevindik